Kali Therapeutics pivots from Chinese drug acquisitions to focus on its own growing pipeline
read at Endpoints ↗Positive
Kali Therapeutics, the winner of the Endpoints 11 2026 competition, initially explored the possibility of purchasing drug candidates from China.
The company ultimately chose to rely on its own research and development, and its in-house pipeline is now described as thriving.
Co-founders Weihao Xu (CEO), Min Bao (CMO), John Wang (CSO) and Jay Zhao (CTO) lead the firm from its headquarters in San Mateo, California.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Endpoints 11 2026 winner Kali looked at China for pipeline drugs, then turned in-house”
read at Endpoints ↗83 words · retrieved Sep 25
comments(0)
5-min edit window · permanent after that